Berger Rachel Pardes, Adelson P David, Pierce Mary Clyde, Dulani Tina, Cassidy Laura D, Kochanek Patrick M
Department of Pediatrics, Child Advocacy Center, Children's Hospital of Pittsburgh, Pennsylvania 15217, USA.
J Neurosurg. 2005 Jul;103(1 Suppl):61-8. doi: 10.3171/ped.2005.103.1.0061.
Misdiagnosis of inflicted traumatic brain injury (iTBI) is common. Serum biomarkers may be able to assist in the detection of iTBIs that would otherwise be missed. The authors investigated whether serum concentrations of biomarkers were increased after noninflicted (n)TBI and iTBI in pediatric cases of varying severity.
This prospective, case-control study involved 100 patients (56 with nTBI, 44 with iTBI) and 64 controls. Blood was collected in patients within 12 hours of injury; a subset had serial samples. A single sample was collected from controls. Serum neuron-specific enolase (NSE), S100B, and myelin basic protein concentrations were measured. Abnormal concentrations were defined using receiver-operator characteristic (ROC) curves. The sensitivity and specificity of initial NSE and S100B and peak myelin basic protein concentrations for identifying TBI at ROC curve-defined cutoffs were 71 and 64% (NSE), 77 and 72% (S100B), and 44 and 96% (myelin basic protein), respectively. Eighty-six percent of patients having suffered iTBI had one or more biomarkers increased, including 82% of children with iTBI and a Glasgow Coma Scale score of 15, and two children with iTBI who were initially misdiagnosed. Children with iTBI had a later peak concentration of all three biomarkers and were more likely to have increased myelin basic protein levels at admission compared with patients with nTBI.
Serum NSE, S100B, or myelin basic protein are increased in the majority of children with acute nTBI and iTBI, including well-appearing children with iTBI in whom the diagnosis might otherwise have been missed. Differences in the time course of NSE, S100B, and myelin basic protein after nTBI and iTBI may provide insight into the pathophysiology of iTBI. These serum markers should be prospectively evaluated in a target population of infants.
外伤性脑损伤(iTBI)的误诊很常见。血清生物标志物或许能够帮助检测出原本可能漏诊的iTBI。作者调查了不同严重程度的儿科病例在非外伤性(n)TBI和iTBI后血清生物标志物浓度是否升高。
这项前瞻性病例对照研究纳入了100例患者(56例nTBI,44例iTBI)和64例对照。在受伤后12小时内采集患者血液;一部分患者采集了系列样本。从对照中采集单个样本。检测血清神经元特异性烯醇化酶(NSE)、S100B和髓鞘碱性蛋白浓度。使用受试者工作特征(ROC)曲线定义异常浓度。在ROC曲线定义的临界值下,初始NSE和S100B以及髓鞘碱性蛋白峰值浓度用于识别TBI的敏感性和特异性分别为71%和64%(NSE)、77%和72%(S100B)、44%和96%(髓鞘碱性蛋白)。86%的iTBI患者有一项或多项生物标志物升高,包括82%格拉斯哥昏迷量表评分为15分的iTBI儿童,以及两名最初被误诊的iTBI儿童。与nTBI患者相比,iTBI儿童的所有三种生物标志物峰值浓度出现得更晚,且入院时髓鞘碱性蛋白水平升高的可能性更大。
大多数急性nTBI和iTBI儿童的血清NSE、S100B或髓鞘碱性蛋白升高,包括那些外表正常但可能漏诊的iTBI儿童。nTBI和iTBI后NSE、S100B和髓鞘碱性蛋白的时间进程差异可能有助于深入了解iTBI的病理生理学。这些血清标志物应在目标婴儿群体中进行前瞻性评估。